PF-07868489 for Pulmonary Hypertension
Trial Summary
Do I need to stop my current medications to join the trial?
The trial requires participants with pulmonary arterial hypertension to be on a stable dose of their current PAH medications. The protocol does not specify if other medications need to be stopped.
What data supports the effectiveness of the drug PF-07868489 for pulmonary hypertension?
What is the purpose of this trial?
This trial is testing a new medicine called PF-07868489. It aims to see how safe it is and how it behaves in both healthy adults and those with pulmonary arterial hypertension (PAH). The study will help understand how the medicine moves through the body and its effects.
Research Team
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Eligibility Criteria
This trial is for healthy adults and those with pulmonary arterial hypertension (PAH), a type of high blood pressure affecting the lungs. Participants should have a BMI between 16 to 32 kg/m2 and weigh over 50 kg. It's not clear who can't join because the exclusion criteria are missing.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Part A: Single Ascending Dose
An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants.
Part B: Repeat Doses
A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- PF-07868489
- Placebo for PF-07868489
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University